Publications by authors named "Florencia Inciarte"
Efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime®) vs. Gonal-f® in women undergoing ovarian stimulation for IVF: A randomized, multicenter, evaluator-blinded, non-inferiority study.
JBRA Assist Reprod
October 2021
Objective: We compared the efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime®) with Gonal-f® in women undergoing ovarian stimulation for in-vitro fertilization.
Methods: This randomized (1:1), multicenter, assessor-blinded, non-inferiority, parallel-group, controlled study conducted at four infertility clinics in Argentina included infertile normogonadotropic women with ages below 39 years, with menstrual cycles of 25/35 days and a body mass index of 18-32 kg/m2 undergoing assisted reproductive technology therapy. During a 5-day fixed-dose phase, the women received 225 IU/day of Folitime® (n=49) or Gonal-f® (n=44), followed by a dose-adaptation phase up to a maximum of 450 IU/day.
Article Synopsis
- A 38-year-old woman sought surrogacy treatment after losing her uterus and had normal hormonal and ovarian function, while her husband's semen quality was fine.
- The surrogate, a 39-year-old woman with two children and a close relationship with the patient, underwent hormone stimulation, resulting in six oocytes and four embryos, leading to a successful pregnancy and birth.
- A lawsuit arose post-birth for the baby to be registered with the biological parents’ names, which was granted by a judge citing Argentine law, highlighting a lack of regulatory framework for surrogacy in the country that may lead to future conflicts.